ALNY | tickerfilter.com

Fundamental analysis

52%

Profitability 47%

Dept financing 41%

Liquidity 75%

Performance 55%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.40%

1 Month

-2.33%

3 Months

-25.47%

6 Months

-29.56%

1 Year

29.17%

2 Year

114.16%

Key data

Stock price

$320.51

P/E Ratio

167.44

DAY RANGE

$319.51 - $328.28

EPS

$2.39

52 WEEK RANGE

$205.87 - $495.55

52 WEEK CHANGE

$31.08

MARKET CAP

52.535 B

YIELD

N/A

SHARES OUTSTANDING

132.623 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

07-31-2025

BETA

1.18

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,041,769

AVERAGE 30 VOLUME

$1,400,637

Company detail

CEO: Yvonne L. Greenstreet
Region: US
Website: alnylam.com
Employees: 2,000
IPO year: 2004

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Alnylam Pharmaceuticals, Inc. focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS/ocular) diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

ALNY - ALNYLAM PHARMACEUTICALS, INC.